Objective:This study aims to investigate the clinical efficacy of trimetazidine combined with Wenxin granule in patients with heart failure(HF)and its influence on serum inflammatory markers.Methods:This randomized controlled study enrolled 120 HF patients admitted in Maanshan Shiqiye Hospital between January 2018 and June 2019.The patients were divided into control group(n=60,trimetazidine therapy)and combined treatment group(n=60,trimetazidine com-bined Wenxin granule treatment).One month was regard as a course.After 3 continuous courses,clinical therapeutic effect,inflammatory factors,cardiac function and incidence of adverse reactions were compared between two groups.Re-sults:Total effective rate of combined treatment group was significantly higher than that of control group(96.7％vs.71.7％,P＜0.001).Compared with participants in control group after treatment,those in combined treatment group had significant lower interleukin(IL)-6[(53.63±6.34)ng/L vs.(45.23±6.12)ng/L],IL-17[(9.68±3.37)ng/L vs.(7.55±2.69)ng/L],tumor necrosis factor(TNF-α)[(13.81±2.13)ng/L vs.(10.29±1.04)ng/L],brain natriuretic peptide(BNP)[(98.65±10.23)ng/L vs.(51.28±8.16)ng/L],left ventricular end-diastolic diameter(LVEDd)[(50.71±6.78)mm vs.(42.32±6.39)mm]and left ventricular end-systolic diameter(LVESd)[(42.43±3.56)mm vs.(33.91±3.25)mm],and significant higher left ventricular ejection fraction(LVEF)[(44.92±4.36)％vs.(54.23±4.27)％](P＜0.001 all).We detected significant lower incidence of adverse reactions(8.3％vs.23.3％,P=0.024)in combined treatment group compared to control group.Conclusion:Trimetazidine combined with Wenxin granule is effec-tive in patients with heart failure,which could significantly reduce serum inflammatory factors,improve cardiac function and reduce incidence of adverse reactions.

Objective:This study aims to investigate the clinical efficacy of trimetazidine combined with Wenxin granule in patients with heart failure(HF)and its influence on serum inflammatory markers.Methods:This randomized controlled study enrolled 120 HF patients admitted in Maanshan Shiqiye Hospital between January 2018 and June 2019.The patients were divided into control group(n=60,trimetazidine therapy)and combined treatment group(n=60,trimetazidine com-bined Wenxin granule treatment).One month was regard as a course.After 3 continuous courses,clinical therapeutic effect,inflammatory factors,cardiac function and incidence of adverse reactions were compared between two groups.Re-sults:Total effective rate of combined treatment group was significantly higher than that of control group(96.7％vs.71.7％,P＜0.001).Compared with participants in control group after treatment,those in combined treatment group had significant lower interleukin(IL)-6[(53.63±6.34)ng/L vs.(45.23±6.12)ng/L],IL-17[(9.68±3.37)ng/L vs.(7.55±2.69)ng/L],tumor necrosis factor(TNF-α)[(13.81±2.13)ng/L vs.(10.29±1.04)ng/L],brain natriuretic peptide(BNP)[(98.65±10.23)ng/L vs.(51.28±8.16)ng/L],left ventricular end-diastolic diameter(LVEDd)[(50.71±6.78)mm vs.(42.32±6.39)mm]and left ventricular end-systolic diameter(LVESd)[(42.43±3.56)mm vs.(33.91±3.25)mm],and significant higher left ventricular ejection fraction(LVEF)[(44.92±4.36)％vs.(54.23±4.27)％](P＜0.001 all).We detected significant lower incidence of adverse reactions(8.3％vs.23.3％,P=0.024)in combined treatment group compared to control group.Conclusion:Trimetazidine combined with Wenxin granule is effec-tive in patients with heart failure,which could significantly reduce serum inflammatory factors,improve cardiac function and reduce incidence of adverse reactions.